Lexeo Therapeutics Income Statement (2022-2026) | LXEO

Income Statement Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter) 0.53M
Operating items
Research & Development (Quarter) 15.36M11.39M16.44M11.24M17.25M-44.92M15.74M16.56M23.42M18.37M17.17M14.72M15.70M15.70M
Wages, Salaries and Other (Quarter) 0.35M0.28M0.42M0.31M0.33M0.34M0.45M0.42M0.46M
Selling, General & Administrative (Quarter) 2.65M3.81M2.85M2.74M3.03M6.76M7.55M6.99M8.12M9.02M16.63M15.97M5.95M6.91M6.63M
Restructuring Costs (Quarter) 4.89M3.96M4.34M11.80M12.56M12.24M2.87M9.32M4.71M
Other Operating Expenses (Quarter) 53.13M-4.89M-3.96M-4.34M-11.80M-12.56M-12.24M-2.87M6.89M-4.71M
Operating Expenses (Quarter) 18.01M15.20M19.29M13.97M20.27M14.97M23.29M23.55M31.54M27.38M33.80M30.69M21.65M23.12M22.33M
Operating Income (Quarter) -17.48M-15.20M-19.29M-13.97M-20.27M-14.97M-23.29M-23.55M-31.54M-27.38M-33.80M-30.69M-21.65M-23.12M-22.33M
EBIT (Quarter) -17.48M-15.20M-19.29M-13.97M-20.27M-14.97M-23.29M-23.55M-31.54M-27.38M-33.80M-30.69M-21.65M-23.12M-22.33M
Non-operating items
Non Operating Investment Income (Quarter) 0.05M0.04M-0.33M
Interest & Investment Income (Quarter) 0.46M0.68M0.69M0.59M0.49M1.10M1.65M2.35M2.09M1.47M-0.01M1.27M1.46M2.21M2.11M
Other Non Operating Income (Quarter) -0.00M-0.00M0.00M-0.01M-0.01M-0.00M-0.00M0.69M-0.00M-0.01M-0.01M-5.50M-0.00M
Non Operating Income (Quarter) 0.43M0.62M0.63M0.53M0.17M0.79M1.61M2.31M2.05M1.46M1.15M4.58M1.36M2.20M2.14M
Net income details
EBT (Quarter) -17.05M-14.58M-18.66M-13.44M-20.11M-14.19M-21.68M-21.24M-29.49M-25.92M-32.66M-26.10M-20.28M-21.45M-20.20M
Profit After Tax (Quarter) -17.05M-14.60M-18.66M-13.44M-20.11M-14.19M-21.68M-21.24M-29.49M-25.92M-32.66M-26.10M-20.28M-21.00M-20.20M
Income from Non-Controlling Interests (Quarter) -0.27M-0.26M
Income from Continuing Operations (Quarter) -17.05M-14.58M-18.66M-13.44M-20.11M-14.19M-21.68M-21.24M-29.49M-25.92M-32.66M-26.10M-20.28M-21.45M-20.20M
Consolidated Net Income (Quarter) -17.05M-14.58M-18.66M-13.44M-20.11M-14.19M-21.68M-21.24M-29.49M-25.92M-32.66M-26.10M-20.28M-21.45M-20.20M
Income towards Parent Company (Quarter) -17.05M-14.58M-18.66M-13.44M-20.11M-14.19M-21.68M-21.24M-29.49M-25.92M-32.66M-26.10M-20.28M-21.45M-20.20M
Net Income towards Common Stockholders (Quarter) -17.05M-14.58M-18.66M-13.44M-20.11M-14.19M-21.68M-21.24M-29.49M-25.92M-32.66M-26.10M-20.28M-21.45M-20.20M
Additional items
EPS (Basic) (Quarter) -10.38-8.94-11.58-8.30-12.36-2.65-0.77-0.64-0.89-0.82-0.99-0.60-0.33-0.40-0.25
EPS (Diluted) (Quarter) -10.38-8.94-11.58-8.30-12.36-2.65-0.77-0.64-0.89-0.82-0.99-0.60-0.33-0.40-0.25
Shares Outstanding (Quarter) 1.64M1.63M1.61M1.62M1.63M5.35M27.98M33.00M33.06M31.79M33.11M43.57M60.98M53.65M81.18M
Shares Outstanding (Diluted) (Quarter) 1.64M1.63M1.61M1.62M1.63M5.35M27.98M33.00M33.06M31.79M33.11M43.57M60.98M53.65M81.18M
EBITDA (Quarter) -17.48M-15.20M-19.29M-13.97M-20.27M-14.97M-23.29M-23.55M-31.54M-27.38M-33.80M-30.69M-21.65M-23.12M-22.33M
Interest Expenses (Quarter) 0.27M0.04M0.55M0.51M8.99M0.05M18.24M17.51M5.52M0.53M0.53M9.24M8.70M0.54M2.76M